Christopher Nelson - Feb 6, 2024 Form 4 Insider Report for QSAM Biosciences, Inc. (QSAM)

Role
EVP Corp Dev & General Counsel
Signature
/s/ Christopher Nelson
Stock symbol
QSAM
Transactions as of
Feb 6, 2024
Transactions value $
$0
Form type
4
Date filed
2/13/2024, 04:00 PM
Previous filing
Jun 23, 2023
Next filing
May 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction QSAM Common Stock Conversion of derivative security $26K +8.68K +5.01% $3.00 182K Feb 6, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction QSAM Series B Convertible Preferred Stock Conversion of derivative security -$26K 0 Feb 6, 2024 Common Stock 8.68K $3.00 Direct F1
holding QSAM Options to buy common stock 12.5K Feb 6, 2024 Common Stock 12.5K $10.00 Direct F2
holding QSAM Options to buy common stock 2.88K Feb 6, 2024 Common Stock 2.88K $14.40 Direct F3
holding QSAM Options to buy common stock 60 Feb 6, 2024 Common Stock 60 $20.00 Direct
holding QSAM Options to buy common stock 255 Feb 6, 2024 Common Stock 255 $20.00 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Series B Convertible Preferred Stock was convertible into common stock at any time and had no expiration date. Pursuant to an Exchange Agreement signed by and between the Company and all Series B Preferred Stockholders as of 11/18/23, the Series B Preferred Stock was automatically exchangeable for common stock of the Issuer at a price of $3.00 per share upon the Issuer listing on Nasdaq or signing an agreement to be acquired.
F2 The option vests annually in two equal installments beginning on 3/3/2023.
F3 The option vested semi-annually in two equal installments beginning on 2/24/2022.